Lannett decline on Connecticut probe seems overdone, says Roth Capital After Lannett fell 17% following the disclosure that it had received subpoenas from Connecticut regarding the pricing of digoxin, Roth Capital does not expect the state to take any further action against the company. The firm does not believe that there has been any collusion on digoxin prices. It keeps a $45 price target and Buy rating on the shares.
Senate Health, Education, Labor & Pensions Committee to hold a hearing The Subcommittee on Primary Health and Aging holds a hearing entitled, "Why Are Some Generic Drugs Skyrocketing In Price?" with President & CEO Vigodman of Teva Pharmaceutical and President & CEO Bedrosian of Lannett Company on November 20 at 1 pm. Webcast Link